Dibasic sodium phosphate monohydrate

Anhydrous dibasic sodium phosphate [7558-79-4] Dibasic sodium phosphate dihydrate [10028-24-7] Dibasic sodium phosphate dodecahydrate [10039-32-4] Dibasic sodium phosphate heptahydrate [7782-85-6] Dibasic sodium phosphate hydrate [10140-65-5] Dibasic sodium phosphate monohydrate [118830-14-1]... 

To be reconstituted with 1 mL sterile WFI containing 1.0 mg Poloxamer 188 (0.15mg/mL) Per 5mg vial 33.0mg mannitol 3.0mg sodium phosphate monobasic monohydrate 8.8 mg sodium phosphate dibasic heptahydrate Per vial 10.6 mg mannitol IV 15.9mg/mL L-alanine 12.6-14.3 mg of dibasic sodium phosphate... 

Per vial 23 mg glycine 1.6 mg SC dibasic sodium phosphate heptahydrate 0.55 mg monobasic sodium phosphate monohydrate... 

To be reconstituted with sterile WFI (pH approximately 7.2) Per lOmL 500 mg sucrose 0.5 mg polysorbate 80 2.2 mg monobasic sodium phosphate monohydrate 6.1 mg dibasic sodium phosphate dihydrate IV infusion... 

Phosphate-Cysteine-EDTA Buffer Solution Dissolve 7.1 g of anhydrous dibasic sodium phosphate in about 800 mL of water, and then dissolve in this solution 14.0 g of disodium EDTA dihydrate and 6.1 g of cysteine hydrochloride monohydrate. 

Disodium hydrogen phosphate Disodium hydrogen phosphate dodecahydrate Dibasic sodium phosphate Dinatrii phosphas anhydricus Dinatrii phosphas dihydricus Dinatrii phosphas dodecahydricus Dibasic sodium phosphate Note that the BP 2004 and PhEur 2005 contain three separate monographs for the anhydrous, the dihydrate, and the dodecahydrate the JP 2001 contains one monograph for the dodecahydrate and the USP 28 contains one monograph for the anhydrous, the monohydrate, the dihydrate, the heptahy-drate, and the dodecahydrate. See also Section 8. 

Each syringe deiivers 0.8 ml (40 mg) of DP. Each vial contains approximately 0.9 mL of solution to deiiver 0.8 ml (40 mg) of DP. Each 0.8 ml contains 40 mg of adaiimumab, 4.93 mg of sodium chioride, 0.69 mg of monobasic sodium phosphate dihydrate, 1.22 mg of dibasic sodium phosphate dihydrate, 0.24 mg of sodium citrate, 1.04 mg of citric acid monohydrate, 9.6 mg of mannitol, 0.8 mg of polysorbate 80 and water for injection, USP. Sodium hydroxide added as necessary to adjust pH. 

For subcutaneous injection after reconstitution with either SWFi, LISP for single-dose ampules or BWFI (0.9% benzyl alcohol), LISP for multiple-dose vials. Each ampule contains either 37.5, 75, or 150 lU rFSH, 30 mg of sucrose, 1.11 mg of dibasic sodium phosphate, and 0.45 mg of monobasic sodium phosphate monohydrate. 0-phosphoric acid and/or sodium hydroxide may be used prior to iyophiiization for pH adjustment, it may contain up to 15% of oxidized FSH. 

M NaCl. To 900 mL of deionized water, add 0.53 g of monobasic sodium phosphate monohydrate (NaH2P04-H20) and 0.87 g of dibasic sodium phosphate anhydrous (Na2HP04). Add 8.77 g of sodium chloride (NaCl) and dilute to a final volume of 1,000 mL with deionized water. 

In addition, each package consisting of five labeling units contains also five vials of methylene blue injection 1% USP (10 mg methylene blue USP in 1 ml water for injection), and five vials containing 0.003 M monobasic sodium phosphate USP and dibasic sodium phosphate USP in 4.5 ml of 0.9% sodium chloride injection USP. Each milliliter contains 0.276 mg monobasic sodium phosphate monohydrate, 0.142 mg dibasic sodium phosphate anhydrous, and 9 mg sodium chloride in water for injection for a sufficient amount. A mixture of methylene blue in phosphate buffer is used for stabilization of the Tc-HMPAO complex (Amersham Healthcare 1995). 

H20. Cream contains calcipotriene monohydrate equivalent to 50 pg/g anhydrous calcipotriene in a cream base of cetearyl alcohol, ceteth-20, diazolidinyl urea, dichlo-robenzyl alcohol, dibasic sodium phosphate, edetate disodium, glycerin, mineral oil, petrolatum, and water. 

Fleat 75% of the water to 70°C in a suitable vessel. Add the monobasic sodium phosphate monohydrate, anhydrous dibasic sodium phosphate, propylene glycol, and benzyl alcohol to the vessel with agitation, maintaining the temperature at 70°C. 

There have been several studies of weekly administration of exenatide, using a formulation of exenatide microspheres with poly (D,L-lactide-co-glycolide), which is available as a powder for dissolution in a solvent that includes carmellose sodium, sodium chloride, polysorbate 20, monobasic sodium phosphate monohydrate, and dibasic sodium phosphate heptahydrate. The 2-mg dose of exenatide once in suspension should be injected immediately [49 ]. 

Calcium oxalate monohydrate Calcium phosphate (dibasic) Calcium pyrophosphate Calcium sodium phosphate Calcium sulfate Calcite... 

Avastin Avastin is used for the treatment of colorectal cancer. It is supplied in 100 and 400 mg dosages. The 100 mg formulation consists of 240 mg a,a-trehalose dihydrate, 23.2 mg sodium phosphate (monobasic, monohydrate), 4.8mg sodium phosphate (dibasic, anhydrous), 1.6mg polysorbate 20 and water-for-injection. 

Formulation Aranesp is formulated as a sterile, colorless, preservative-free protein solution for intravenous (IV) or subcutaneous (SC) administration. There are two formulations the polysorbate solution includes excipients such as polysorbate 80, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and sodium chloride in water-for-injection while the albumin solution contains albumin, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and sodium chloride in water-for-injection. The pH for both formulations is 6.2 + 0.2. 

A new formulation of a saline laxative, Visicol, that is useful to prepare patients for procedures, was approved for use in 2001. Each 2-g tablet contains 1.102 g sodium phosphate monobasic monohydrate and 0.398 g sodium phosphate dibasic anhydrous, for a total of 1.5 g sodium phosphate. Visicol tablets, taken in two doses of 30 g approximately 12 hours apart, induce diarrhea that rapidly and effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. 

CHO-expressed glycoprotein] Pharmaceuti- (single-dose vial) cals mL (pH = 5.5) 43.9mg sodium chloride 63.5mg sodium phosphate monobasic monohydrate 10.7 mg sodium phosphate dibasic heptahydrate 0.05 mg polysorbate 80 0.9% NaCl containing 1% HSA prior to administration)... 

Per 1 mL 2.5 mg albumin (human) 1.2 mg sodium phosphate monobasic monohydrate 1.8 mg sodium phosphate dibasic anhydrate 0.7 mg sodium citrate 5.8 mg sodium chloride 6.8 pg citric acid in WFI, USP... 

Per 1 mL polysorbate solution 0.05mg/mL polysorbate 80 2.12mg/mL sodium phosphate monobasic monohydrate 0.66mg/mL sodium phosphate dibasic anhydrous 8.18mg/mL sodium chloride (pH 6.2 0.2)... 

Per 1 mL 1.36 mg glycine 36.0 mg mannitol 1.04mg sodium phosphate dibasic anhydrous 0.36 mg sodium phosphate monobasic monohydrate... 

Each milliliter contains 5 mg of Daclizumab and 3.6 mg of sodium phosphate monobasic monohydrate, 11 mg of sodium phosphate dibasic heptahydrate, 4.6 mg of sodium chloride, 0.2 mg of polysorbate 80 and may contain hydrochloric acid or sodium hydroxide to adjust the pH to 6.9. No preservatives are added. 

Two formulations contain excipients as follows polysorbate solution contains 0.05 mg of polysorbate 80, 2.12 mg of sodium phosphate monobasic monohydrate, 0.66 mg of sodium phosphate dibasic anhydrous, and 8.18 mg of sodium chloride in water for injection, LISP (per 1 mL) at pH 6.2 + 0.2. Albumin solution contains 2.5 mg of albumin (human), 2.23 mg of sodium phosphate monobasic monohydrate, 0.53 mg of sodium phosphate dibasic anhydrous, and 8.18 mg of sodium chloride in water for injection, LISP (per 1 mL) at pH 6.0 + 0.3. 

Each vial contains 37 mg of alpha-galactosidase beta as well as 222 mg of mannitol, 20.4 mg of sodium phosphate monobasic monohydrate, and 59.2 mg of sodium phosphate dibasic heptahydrate. Following reconstitution as directed, 35 mg of agalactosidase beta (7 ml) may be extracted from each vial. 

Each vial also contains 1.36 mg of glycine, 36.0 mg of mannitol, 1.04 mg of sodium phosphate dibasic anhydrous, and 0.36 mg of sodium phosphate monobasic monohydrate. 

Calcium citrate Calcium gluconate Calcium hydroxide Calcium lactate Calcium phosphate monobasic anhydrous Calcium phosphate monobasic monohydrate Calcium phosphate tribasic Calcium pyrophosphate Disodium citrate Glycine Hydrochloric acid Potassium acetate Potassium alum dodecahydrate Potassium citrate Potassium phosphate Potassium phosphate dibasic Potassium phosphate tribasic Potassium sodium tartrate Potassium sodium tartrate tetrahydrate Potassium tripolyphosphate Sodium acid pyrophosphate Sodium alum Sodium citrate Sodium fumarate Sodium lactate... 

Citric acid Citric acid monohydrate Ethylenediamine Glycine Hydrochloric acid Magnesium carbonate Magnesium oxide Potassium carbonate Potassium citrate Potassium metaphosphate Potassium phosphate Potassium phosphate dibasic Sodium acetate anhydrous Sodium citrate Sodium hydroxide Sodium lactate Sodium phosphate Sodium phosphate dibasic anhydrous Sodium phosphate dibasic heptahydrate Sodium tri metaphosphate... 

Calcium phosphate monobasic monohydrate Sodium fluoride Sodium phosphate dibasic dihydrate... 

Calcium phosphate monobasic anhydrous Choline bitartrate Cobalt diacetate Sodium phosphate dibasic dihydrate mineral supplement, animal feed Calcium phosphate dibasic Ferrous sulfate monohydrate... 

---